



# Drug Prior Authorization Form Rituxan (rituximab)

The purpose of this form is to obtain information required to assess your drug claim.

**IMPORTANT:** Please answer all questions. Your claim assessment will be delayed if this form is incomplete or contains errors.

**Any costs incurred for the completion of this form are the responsibility of the plan member/patient.**

Canada Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of assessing eligibility for this drug and for administering the group benefits plan. For a copy of our Privacy Guidelines, or if you have questions about Canada Life’s personal information policies and practices (including with respect to service providers), refer to [www.canadalife.com](http://www.canadalife.com) or write to Canada Life’s Chief Compliance Officer.

I authorize Canada Life, any healthcare provider, my plan administrator, any insurance or reinsurance company, administrators of government benefits or patient assistance programs or other benefits programs, other organizations, or service providers working with Canada Life or any of the above, located inside or outside Canada, to exchange personal information when relevant and necessary for these purposes. I understand that personal information may be subject to disclosure to those authorized under applicable law within or outside Canada.

I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benefits plan. I acknowledge that providing consent will help Canada Life to assess my claim and that refusing to consent may result in delay or denial of my claim. Canada Life reserves the right to audit the information provided on this form at any time and this consent extends to any audit of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.

I also consent to the use of my personal information for Canada Life and its affiliates’ internal data management and analytics purposes.

If the patient is a person other than myself, I confirm that the patient has given their consent to provide their personal information and for Canada Life to use and disclose it as set out above.

I certify that the information given below is true, correct, and complete to the best of my knowledge. Failure to provide true, correct and complete information on this form could result in revocation of any approval decision, a requirement to repay paid claims or other appropriate action.

Plan Member’s signature: \_\_\_\_\_

Date: \_\_\_\_\_

## Form Completion Instructions:

1. Complete “Patient Information” sections.
2. Have the prescribing physician complete the “Physician Information” sections.
3. Send all pages of the completed form to us by mail, fax or email as noted below.

**Note:** As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

**Mail to:** The Canada Life Assurance Company  
Drug Claims Management  
PO Box 6000  
Winnipeg MB R3C 3A5

**Fax to:** The Canada Life Assurance Company  
Fax 1-204-946-7664  
Attention: Drug Claims Management

**Email to:** [cldrug.services@canadalife.com](mailto:cldrug.services@canadalife.com)  
Attention: Drug Claims Management

For additional information regarding Prior Authorization and Health Case Management, please visit our Canada Life website at [www.canadalife.com](http://www.canadalife.com) or contact Group Customer Contact Services at 1-800-957-9777. Deaf or hard of hearing and require access to a telecommunications relay service? Please contact us at 711 for TTY to Voice or 1-800-855-0511 for Voice to TTY.

(Continued on next page)

**Plan Member Information – Complete all sections of this page (please print)**

Plan Member:		Patient Name:	
Plan Name:	Plan Number:	Plan Member ID Number:	
Patient Date of Birth (DD/MM/YYYY):	Address (number, street, city, province, postal code):		

Please indicate preferred contact number and if there are any times when telephone contact with you about your claim would be most convenient.

May we contact you by email? (Note that some correspondence may still need to be sent by regular mail).

Yes  No If yes, please provide email address: \_\_\_\_\_

**Tell us if you have been on this drug before**

Is the patient currently on, or previously been on this drug?  Yes  No

If Yes, a) indicate start date (DD/MM/YYYY): \_\_\_\_\_

b) coverage provided by: \_\_\_\_\_

(if coverage is not provided by Canada Life please provide pharmacy print-out showing purchase of this drug)

**Tell us if you have coverage with any other benefits plan**

Does the patient have drug coverage under any other group benefits plan?  Yes  No

If Yes, name of other Insurance Company: \_\_\_\_\_

If other plan is with Canada Life, tell us the plan and ID number: \_\_\_\_\_

Name of plan member: \_\_\_\_\_

Relationship to patient: \_\_\_\_\_

**Provide details and attach documentation of acceptance or decline:**

\_\_\_\_\_

\_\_\_\_\_

**Tell us about any Provincial or other coverage you may have**

Does the patient have coverage under a provincial program or from any other source?  Yes  No

If Yes, name of program or other source: \_\_\_\_\_

Provide details and attach documentation of acceptance or decline: \_\_\_\_\_

Is the patient currently receiving disability benefits for the condition for which this drug has been prescribed?  Yes  No

**Tell us about any Patient Assistance Program you might be enrolled in**

Has the patient enrolled in the patient assistance program for this drug?  Yes  No

If Yes, please provide the following information:

1. Patient assistance program patient ID Number: \_\_\_\_\_

2. Patient assistance program contact person name and phone number:

Contact Name: \_\_\_\_\_ Phone Number: \_\_\_\_\_

(Continued on next page)

**Note to Physician:** In order to assess a patient's claim for this drug, we require detailed information on the patient's prescription drug history as requested below.

**Attach extra information if necessary. GENETIC TEST RESULTS ARE NOT REQUIRED**

**Physician's Information (please print)**

Name of prescribing physician: \_\_\_\_\_

Specialty: \_\_\_\_\_

Address (number, street, city, province, postal code): \_\_\_\_\_

Telephone Number (including area code): \_\_\_\_\_

Fax Number (including area code): \_\_\_\_\_

1. Prescribed dosage and regimen:

- Two 1000mg infusions scheduled two weeks apart
- 375mg/m<sup>2</sup> once weekly for 4 doses
- Other (please specify): \_\_\_\_\_

Provide rationale: \_\_\_\_\_

2. Health Canada indication (include date of initial diagnosis) (MM/YYYY): \_\_\_\_\_

- Relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
- Stage III/IV follicular non-Hodgkin's lymphoma
- B-cell chronic lymphocytic leukemia (B-CLL)
- Rheumatoid arthritis
- Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)
- Other (Approved by Health Canada): \_\_\_\_\_

Complete questions 1 - 6 and Other Condition (Health Canada approved)

**Genetic test results are not required**

Is this drug being prescribed in accordance with approved Health Canada indications<sup>1</sup>?

- Yes, complete questions 1 - 6 and Physician's Information
- No, prescribed use is not approved by Health Canada: \_\_\_\_\_

Complete questions 1 - 6 and Off Label use

**Physician's Information (continued) (please print)**

***'Approved Health Canada Indications and Clinical Use for Rituxan:***

- The treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma.
- The treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.
- The treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, Bcell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.
- Maintenance treatment of patients with follicular non-Hodgkin's lymphoma who have responded to induction therapy with either CHOP or CHOP plus RITUXAN.
- Single-agent maintenance treatment of previously untreated patients with advanced follicular non-Hodgkin's lymphoma with high tumour burden and who have responded to induction therapy with either CHOP plus RITUXAN or CVP plus RITUXAN.
- The treatment of patients with previously untreated or previously treated B-cell chronic lymphocytic leukemia (B-CLL), Binet Stage B or C, in combination with fludarabine and cyclophosphamide.
- In combination with methotrexate is indicated in adult patients: to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.
- In combination with glucocorticoids is indicated for the induction of remission in adult patients with severely active Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).

3. What is the anticipated duration of treatment with this drug? \_\_\_\_\_

4. Where will treatment be administered?  Home  Physician's Office  Private clinic  Hospital in-patient  Hospital out-patient

5. Please provide medical rationale why Rituxan has been prescribed instead of an alternate drug in the same therapeutic class.

\_\_\_\_\_

\_\_\_\_\_

**6. Drug and Treatment History – must be completed for every request.**

Drug(s) and Treatment(s) past and present	Dosing Regimen	Start Date (DD/MM/YYYY)	End Date (DD/MM/YYYY)	Clinical Results/Outcome
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____

**Non-Hodgkin's lymphoma – Genetic test results are not required**

Does the patient have:

Relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma?  Yes  No

Diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) and Rituxan will be prescribed in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy?  Yes  No

Previously untreated Stage III/IV follicular non-Hodgkin's lymphoma and Rituxan will be prescribed in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy?  Yes  No

Follicular non-Hodgkin's lymphoma who have responded to induction therapy with either CHOP or CHOP plus RITUXAN and Rituxan will be prescribed as Maintenance treatment?  Yes  No

Advanced follicular non-Hodgkin's lymphoma with high tumour burden and has responded to induction therapy with either CHOP plus RITUXAN or CVP plus RITUXAN and is previously untreated and Rituxan will be prescribed as single-agent maintenance treatment?  Yes  No

**B-cell chronic lymphocytic leukemia (B-CLL) – Genetic test results are not required**

Does the patient have B-cell chronic lymphocytic leukemia Binet Stage B or C and Rituxan will be prescribed in combination with fludarabine and cyclophosphamide?  Yes  No

**Rheumatoid Arthritis – Genetic test results are not required**

Swollen joint count	Results of the following and date (DD/MM/YYYY) ESR _____ CRP _____
Rheumatoid Factor Positive <input type="checkbox"/> Yes <input type="checkbox"/> No	
Current results and date of one of the following (DD/MM/YYYY) _____ CDAI _____ DAS28 _____ HAQ _____	

Drug(s) and Treatment(s) past and present	Dosing Regimen	Start Date (DD/MM/YYYY)	End Date (DD/MM/YYYY)	Clinical Results/Outcome
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____

**Granulomatosis with Polyangiitis (GPA, also known as Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)  
– Genetic test results are not required**

Does the patient have severely active disease?  Yes  No

Will Rituxan be prescribed in combination with glucocorticoids for the induction of remission?  Yes  No

**Other condition (Health Canada approved) – Genetic test results are not required**

Please provide any relevant information related to the disease and attach supporting documentation.

\_\_\_\_\_

\_\_\_\_\_

**Off-label use – Genetic test results are not required**

**Questions 1-6 must be completed.**

Is there clinical evidence supporting the off-label use of this drug?  Yes  No

Provide clinical literature/studies to support the request for off-label use, such as:

- At least two Phase II or two Phase III clinical trials showing consistent results of efficacy; and
- Published recommendations in evidence-based guidelines supporting its use.

Provide medical rationale why Rituxan has been prescribed off-label instead of an alternate drug with an approved indication for this condition.

\_\_\_\_\_

\_\_\_\_\_

Provide any pertinent medical history or information to support this off-label request.

\_\_\_\_\_

\_\_\_\_\_

If this is a renewal request, provide documentation showing treatment efficacy since previous request.

**Note for Physician: To be eligible for reimbursement, Canada Life may require your patient to purchase a drug requiring prior authorization from a pharmacy designated by Canada Life. If applicable, a health case manager will contact you with further information.**

**I certify that the information provided is true, correct, and complete.**

Physician’s Signature: \_\_\_\_\_ Date: \_\_\_\_\_

License Number: \_\_\_\_\_

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit. The completed form can be returned to Canada Life by mail, fax, or email.

**Note:** As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

**Mail to: The Canada Life Assurance Company  
Drug Claims Management  
PO Box 6000  
Winnipeg MB R3C 3A5**

**Fax to: The Canada Life Assurance Company  
Fax 1-204-946-7664  
Attention: Drug Claims Management**

**Email to: [cldrug.services@canadalife.com](mailto:cldrug.services@canadalife.com)  
Attention: Drug Claims Management**